Postprandial Glucose: Marker or Risk Factor?

Postprandial glucose (PPG) has a noxious effect on the vascular endothelium, which is mainly mediated by oxidative stress. This condition leads to endothelial activation and dysfunction, two prerequisites for the onset of cardiovascular disease (CVD) (1). The importance of PPG is reflected in the creation of guidelines by the International Diabetes Federation (IDF) for the management of postmeal glucose (http://www.idf.org/guidelines/postmeal-glucose). In these guidelines, the statement “Postmeal and postchallenge hyperglycemia are independent risk factors for macrovascular disease” was rated as Level 1+, i.e., the data were derived from well-conducted meta-analyses, systematic reviews of randomized controlled trials (RCTs), or RCTs with a low risk of bias. The relationship between postchallenge hyperglycemia and CVD has been addressed by several studies. In the Honolulu Heart Program, the risk of coronary heart disease was increased in Japanese American men aged 45–68 years who had an abnormal oral glucose tolerance test (2). Comparable results were observed in the Chicago Heart Association Detection Project in Industry Study (3), the Paris Prospective Study (4), the Baltimore Longitudinal Study of Aging (5), and the Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe (DECODE) study (6). Furthermore, two meta-analyses provided evidence that hyperglycemia in the non-diabetic range was associated with a higher risk of fatal and nonfatal CVD. They also showed that CVD events increased linearly, with no threshold, along with 2-h postmeal plasma glucose levels (7,8).

Relatively few studies have analyzed postmeal hyperglycemia as a risk factor in CVD development. In the Diabetes Intervention Study (DIS), in type 2 diabetic patients who were monitored for 11 years, postbreakfast glucose levels, rather than fasting glucose, were related to myocardial infarction and death (9). In this issue of Diabetes Care, Cavallet al. (10) add further evidence of the harmful relationship between postmeal glucose levels and CVD events. They present 14 years of follow-up data from the San Luigi Gonzaga Hospital, located near Turin in northwest Italy. They assessed whether PPG was predictive of cardiovascular events and all-cause mortality. On a day close to their scheduled visit to the outpatient clinic, 505 type 2 diabetic patients obtained daily glucose profiles either in the clinic or at home by self-monitoring. Blood glucose levels from 2 h after breakfast, 2 h after lunch, and before dinner were tested. No blood glucose data were available from after dinner. Using appropriate corrections for confounders, the authors found that HbA1c and blood glucose levels measured 2 h after lunch, but not fasting glucose, predicted cardiovascular events and all-cause mortality. They also made another important observation: they did not see a U-shaped relationship between HbA1c levels and mortality. The strengths of this report include the long follow-up period and the information provided by the authors regarding both the fasting and nonfasting glucose levels. In contrast to the DIS and Baltimore studies, Cavallet al. also assessed the predictive role of HbA1c, which, incidentally, was not significant in their first report on 5 years of follow-up data (11). In addition, their patients were carefully assessed for macro- and microvascular complications. However, this study also has some important limitations: 1) it does not provide the postdinner glucose values, which is important because, at least in Italy, dinner is usually the largest meal; 2) not all of the patients had daily glucose profiles performed at the hospital, where such tests are usually more accurate; 3) although HbA1c values are presented, the results were based on the glucose profiles from a single day, which may not be representative of the patients’ normal metabolic control, especially for those who were monitored inside the hospital; and 4) there was no information on therapeutic changes implemented during this long follow-up period. Anti-diabetic therapies, independent of their hypoglycemic effects, may have a potentially confounding effect on the findings. The authors do not even report hypoglycemic events.

To their credit, Cavallet al. state that their study does not allow them to state that postprandial blood glucose is not only a predictor but also a risk factor for cardiovascular events and death. This is an important point that needs to be clarified. In the IDF guidelines, question 2 was the following: “Is treatment of postmeal hyperglycemia beneficial?” The guidelines’ response, “Treatment with agents that target postmeal plasma glucose reduces vascular events,” was rated 1--; i.e., the data were derived from meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias. Only the DCCT (Diabetes Control and Complications Trial) and the UKPDS (UK Prospective Diabetes Study) were cited in the guidelines, and in the UKPDS specifically, the target glucose level was the fasting level rather than the postprandial level (12). In 2007, when the guidelines were published, important studies that were specifically designed to target PPG were still ongoing. The results of these trials have been disappointing. The HEART2D (Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus) study concluded that in diabetic survivors of acute myocardial infarction, the treatment of postprandial versus basal glucose led to similar HbA1c levels and no difference in the risk of cardiovascular events (13). The NAVIGATOR (Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research) study showed that among patients with impaired glucose tolerance and CVD or risk factors for CVD, the use of nateglinide for 5 years did not reduce the incidence of the composite cardiovascular outcomes (14). The only evidence for a beneficial effect of a specific therapy against PPG comes from the STOP-NIDDM (Study to Prevent NIDDM) (Study to Prevent Non-Insulin-Dependent Diabetes Mellitus) study, in which patients with impaired glucose tolerance who were randomized to acarbose had significantly fewer CVD events than those randomized to placebo (15). A post hoc analysis of the HEART2D study has demonstrated that targeting postprandial versus fasting/premeal glycemia with insulin in older type 2 diabetic patients may be associated with a lower risk of subsequent cardiovascular events (16). In light of these trials, a more critical rating for the statement “Treatment with agents that target postmeal plasma glucose reduces vascular events” would now be, at best, 2+; i.e., data were derived from...
well-conducted case-control or cohort studies with a low risk of confounding bias or chance and a moderate probability that the relationship was causal.

Why is targeting PPG not so effective in reducing cardiovascular events? There are several likely reasons: 1) PPG may merely be a marker of CVD events; 2) PPG is simply a surrogate of a much more complex series of metabolic events occurring in the postprandial period; and 3) the available assessments of PPG postprandial glucose, i.e., the use of a reflectance meter, may not be adequate. It is well established that there is a link not only between insulin resistance and atherosclerosis but also between insulin resistance and other risk factors for CVD. Therefore, PPG may simply mirror a metabolic condition in which several risk factors converge to affect the CVD burden. One of the risk factors that is usually overlooked in the postprandial phase is the concentration of lipids. In the general population, elevated nonfasting triglycerides are associated with an increased risk of myocardial infarction and coronary heart disease (17). The postprandial phase also alters the inflammatory milieu, such as the levels of tumor necrosis factor-α and interleukin-6 (18). It is not known whether a better PPG curbs the prandial proinflammatory state or whether the control of iterative bouts of proinflammatory molecules has any role in the development of CVD. We can also hypothesize that the correction of PPG late in the natural history of the disease is ineffective. Indeed, PPG hits the cardiovascular system early in the course of the disease. Nondiabetic, insulin-resistant subjects show a shorter duration of vasodilatation after a meal with increased fasting vascular resistance (19). In type 2 diabetic patients with no coronary artery disease, elevated PPG is associated with altered myocardial perfusion that is readily corrected when the PPG is controlled (20). Prospective studies are definitively needed in which PPG is specifically corrected early in the course of the disease. As an example, in the HEART2D study, in which the patients had suffered from an acute myocardial infarction, the improvement in PPG might not have been as relevant in terms of CVD prevention as it would be in patients either without CVD or with early-onset type 2 diabetes. Another crucial issue is establishing definitions for PPG and the means of assessing it. Both the San Luigi Gonzaga and the HEART2D studies relied upon glucose levels that were measured with reflectance meters; in addition to the potential problems related to the precision and accuracy of this method, we need PPG metrics that allow clinicians to obtain more robust criteria for both the glycomic quality and variability throughout the day and over a period of several days (21). The methodological limitations of glucose metrics in the published reports may represent another important reason why PPG still may be considered a marker rather than a risk factor for CVD.

ANGELO AVOGARO
MD, PHD

From the Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy.

Corresponding author: Angelo Avogaro, angelo.avogaro@unipd.it.
DOI: 10.2337/dc11-1442

© 2011 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

Acknowledgments—A.A. has received grants and/or consulting fees from Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Merck, Novo Nordisk, and Takeda. No other potential conflicts of interest relevant to this article were reported.

References
1. Ceriello A, Hanefeld M, Leiter L, et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004;164:2090–2095
2. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 1987;36:689–692
3. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J. Post-load plasma glucose and cancer mortality in middle-aged men and women. 12-year follow-up findings of the Chicago Heart Association Detection Project in Industry. Am J Epidemiol 1990;131:254–262
4. Balkau B, Bertrais S, Ducimetiere P, Eschwege E. Is there a glycemic threshold for mortality risk? Diabetes Care 1999;22:696–699
5. Sorkin JD, Muller DC, Fleg JL, Andres R. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 2003;26:2626–2632
6. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe. Lancet 1999;354:617–621
7. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233–240
8. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004;164:2147–2155
9. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577–1583
10. Cavalot F, Pagliarino A, Valle M, Di Martino L, Bonomo K, Massucco P, Anfossi G, Trovati M. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study. Diabetes Care 2011;34:2237–2243
11. Cavalot F, Petrelli A, Traversa M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006;91:813–819
12. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853
13. Raz I, Wilson PW, Strojek K, et al. Effects of prandial versus fasting glycaemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009;32:381–386
14. Holman RR, Haffner SM, McMurray JJ, et al.; NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1463–1476
15. Chiafoss JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. 2003;290:486–494
16. Raz I, Ceriello A, Wilson PW, et al. Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial...
versus fasting/premeal glycemia. Diabetes Care 2011;34:1511–1513
17. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008;300:2142–2152
18. Manning PJ, Sutherland WHF, McGrath MM, de Jong SA, Walker RJ, Williams MJA. Postprandial cytokine concentrations and meal composition in obese and lean women. Obesity (Silver Spring) 2008;16:2046–2052
19. Vigili de Kreutzenberg S, Fadini GP, Boscarini F, et al. Impaired hemodynamic response to meal intake in insulin-resistant subjects: an impedance cardiography approach. Am J Clin Nutr 2011;93:926–933
20. Scognamiglio R, Negut C, de Kreutzenberg SV, Tiengo A, Avogaro A. Effects of different insulin regimes on postprandial myocardial perfusion defects in type 2 diabetic patients. Diabetes Care 2006;29:95–100
21. Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Technol Ther 2009;11(Suppl. 1):S55–S67